Moreover, the potent synergistic anti-proliferative effect of the combination treatment with ABC294640 and vemurafenib was confirmed in two different BRAF mutant colon cancer cells lines RKO and HT-29 with acquired resistance to vemurafenib, which supports the potential therapeutic value of this drug combination in combating drug resistance in BRAF mutant colon cancer. The gene discussed is BRAF; the disease is malignant colon neoplasm.